Patents by Inventor Jason Trama
Jason Trama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11883420Abstract: Methods for treating bladder cancer and solid tumors are disclosed. The methods include administering to a patient a compound of formula 1 Pharmaceutical compositions of compound 1 are also disclosed.Type: GrantFiled: June 8, 2021Date of Patent: January 30, 2024Assignee: VENENUM BIODESIGN, LLCInventors: Brian F. McGuinness, Grant Gallagher, Michael S. McQueney, Rukiye Nazan Eraslan, Gary Schieven, Jason Trama, Axel Metzger, David J. Diller, David E. Kaelin
-
Publication number: 20210290645Abstract: Methods for treating bladder cancer and solid tumors are disclosed. The methods include administering to a patient a compound of formula 1 Pharmaceutical compositions of compound 1 are also disclosed.Type: ApplicationFiled: June 8, 2021Publication date: September 23, 2021Applicant: Venenum Biodesign, LLCInventors: Brian F. McGUINNESS, Grant GALLAGHER, Michael S. McQUENEY, Rukiye NAZAN ERASLAN, Gary SCHIEVEN, Jason TRAMA, Axel METZGER, David J. DILLER, David E. KAELIN
-
Patent number: 11110106Abstract: Methods for treating bladder cancer and solid tumors are disclosed. The methods include administering to a patient a compound of formula 1 Pharmaceutical compositions of compound 1 are also disclosed.Type: GrantFiled: November 12, 2020Date of Patent: September 7, 2021Assignee: VENENUM BIODESIGN, LLCInventors: Brian F. McGuinness, Grant Gallagher, Michael S. McQueney, Rukiye Nazan Eraslan, Gary Schieven, Jason Trama, Venugopalareddy Bommireddy Venkata, Axel Metzger, David J. Diller, David E. Kaelin
-
Patent number: 10845365Abstract: The present invention is directed to a method of detecting a DEK protein in a human urine sample using an ELISA assay. Methods and compositions for detection of DEK using mAb 260-6F9F6 (as detection antibody) and mAb 16-2C9C3 (as capture antibody) in human urine are provided herein. Specifically, the ELISA assay utilizes a capture mAb and a detection mAb to yield a high sensitivity of <50 ng/mL. The presence of DEK in urine is useful in predicting or diagnosing the occurrence of bladder cancer in humans.Type: GrantFiled: July 21, 2017Date of Patent: November 24, 2020Assignee: Medical Diagnostic Laboratories, LLCInventors: Antara Datta, Jason Trama
-
Publication number: 20180011097Abstract: The present invention is directed to a method of detecting a DEK protein in a human urine sample using an ELISA assay. Methods and compositions for detection of DEK using mAb 260-6F9F6 (as detection antibody) and mAb 16-2C9C3 (as capture antibody) in human urine are provided herein. Specifically, the ELISA assay utilizes a capture mAb and a detection mAb to yield a high sensitivity of <50 ng/mL. The presence of DEK in urine is useful in predicting or diagnosing the occurrence of bladder cancer in humans.Type: ApplicationFiled: July 21, 2017Publication date: January 11, 2018Applicant: Medical Diagnostic Laboratories, LLCInventors: Antara Datta, Jason Trama
-
Patent number: 9746473Abstract: The present invention is directed to a method of detecting a DEK protein in a human urine sample using an ELISA assay. Methods and compositions for detection of DEK using mAb 260-6F9F6 (as detection antibody) and mAb 16-2C9C3 (as capture antibody) in human urine are provided herein. Specifically, the ELISA assay utilizes a capture mAb and a detection mAb to yield a high sensitivity of <50 ng/mL. The presence of DEK in urine is useful in predicting or diagnosing the occurrence of bladder cancer in humans.Type: GrantFiled: November 12, 2015Date of Patent: August 29, 2017Assignee: Medical Diagnostic Laboratories, LLCInventors: Antara Datta, Jason Trama
-
Publication number: 20160116475Abstract: The present invention is directed to a method of detecting a DEK protein in a human urine sample using an ELISA assay. Methods and compositions for detection of DEK using mAb 260-6F9F6 (as detection antibody) and mAb 16-2C9C3 (as capture antibody) in human urine are provided herein. Specifically, the ELISA assay utilizes a capture mAb and a detection mAb to yield a high sensitivity of <50 ng/mL. The presence of DEK in urine is useful in predicting or diagnosing the occurrence of bladder cancer in humans.Type: ApplicationFiled: November 12, 2015Publication date: April 28, 2016Applicant: MEDICAL DIAGNOSTIC LABORATORIES, LLCInventors: Antara Datta, Jason Trama
-
Patent number: 9267179Abstract: Methods and compositions useful in the detection and identification of species of Candida are disclosed. The compositions are combinations of oligonucleotides, where the forward primers of the primer pairs have identical sequences, while each reverse primer of the primer pairs has a unique sequence relative to all of the other reverse primers; or the reverse primers of the primer pairs have identical sequences, while each forward primer of the primer pairs has a unique sequence relative to all of the other forward primers. The oligonucleotides also include probes capable of detecting these amplicons, and sequencing primers for determining, in primer extension reactions, the nucleotide sequences contained within the amplicons. The detection of an amplicon indicated that the sample contains at least one isolate of Candida ablicans, Candida glabrata, Candida parapsilosis, or Candida tropicalis, and the nucleotide sequence data is used to determine which of these four Candida species is present.Type: GrantFiled: July 5, 2013Date of Patent: February 23, 2016Assignee: Medical Diagnostic Laboratories, LLCInventors: Jason Trama, Martin E. Adelson, Eli Mordechai
-
Patent number: 9255925Abstract: The present invention is directed to a method of detecting a DEK protein in a human urine sample using an ELISA assay. Methods and compositions for detection of DEK using mAb 260-6F9F6 (as detection antibody) and mAb 16-2C9C3 (as capture antibody) in human urine are provided herein. Specifically, the ELISA assay utilizes a capture mAb and a detection mAb to yield a high sensitivity of <50 ng/mL. The presence of DEK in urine is useful in predicting or diagnosing the occurrence of bladder cancer in humans.Type: GrantFiled: April 22, 2014Date of Patent: February 9, 2016Assignee: Medical Diagnostic Laboratories, LLCInventors: Antara Datta, Jason Trama
-
Patent number: 9145593Abstract: Methods for using oligonucleotides in the detection of Aspergillus fumigatus are disclosed. The oligonucleotides of the invention have nucleotide sequences derived from the gene encoding the cytochrome P450 14 alpha-sterol demethylase (the cyp51A protein) of Aspergillus fumigatus. The oligonucleotides include primers capable of producing amplicons specific to cyp51A in polymerase chain reactions using nucleic acids isolated from Aspergillus fumigatus as templates. The oligonucleotides also include probes capable of detecting these cyp51A-specific amplicons. The oligonucleotides of the invention also include primers for nucleotide sequencing reactions to determine whether an isolate of Aspergillus fumigatus is more tolerant than wild-type Aspergillus fumigatus to a triazole.Type: GrantFiled: September 17, 2012Date of Patent: September 29, 2015Assignee: Medical Diagnostic Laboratories, LLCInventors: Jason Trama, Martin E Adelson, Eli Mordechai
-
Patent number: 9096905Abstract: The present invention provides a method of detecting DNA methylation of a plurality of genes consisting of CDKN2A, BCL2 and NID2 in a urine sample from a human. Methods and compositions are provided herein for detecting and diagnosing bladder cancer by obtaining a urine sample from a human subject suspected of bladder cancer, followed by detecting DNA methylation of CDKN2A, BCL2 AND NID2 in urine samples from the individual. The present method permits specific detection of DNA methylation of the selected gene promoters in urine as a biomarker for bladder cancer in humans.Type: GrantFiled: February 22, 2013Date of Patent: August 4, 2015Assignee: Medical Diagnostic Laboratories, LLCInventors: Michael Scher, Jason Trama
-
Patent number: 8956814Abstract: Disclosed are methods and compositions for conducting assays utilizing real-time polymerase chain reactions (“PCRs”) in detection of serotypes L I, L II, and L III, but not stereotype B, of Chlamydia trachomatis, capable of causing lymphogranuloma venereum (“LGV”). These assays take advantage of a deletion occurring in the cytotoxin gene locus specific to the L I, L II, and L III serotypes. Each assay employs a first primer having a nucleotide sequence flanking one side of the deletion point and a second primer having a nucleotide sequence flanking the other side of the deletion point, wherein the first primer and the second primer are capable of hybridizing respectively to the plus strand and the minus strand of the genome of Chlamydia trachomatis during PCR. Synthesis during PCR of a sequence-specific amplicon containing this deletion point indicates that the sample contains nucleic acid specific to an LGV-causing serotype of Chlamydia trachomatis.Type: GrantFiled: October 23, 2012Date of Patent: February 17, 2015Assignee: Medical Diagnostics Laboratories, LLCInventors: Jason Trama, Eli Mordechai, Martin E. Adelson
-
Patent number: 8932832Abstract: Methods are described herein for detecting and identifying distinct species of nucleic acids, in a single container, for example, from a certain genus of infectious agents or otherwise causative agents comprising, for example, providing a forward PCR primer common to a homologous gene region between the distinct species, and providing a reverse PCR primer common to a homologous gene region between the distinct species, to thereby define a PCR target region amongst the species, and providing a first oligonucleotide probe specific to a nucleic acid sequence within the target region that is characteristic of a first species, providing a second oligonucleotide probe specific to a nucleic acid sequence within the target region that is characteristic of a second species, wherein the first and second oligonucleotide probes are each detectably labeled with distinctly different detectable labels, conducting a PCR reaction in the container by means of the primers to amplify the target region amongst the species, and deType: GrantFiled: August 26, 2011Date of Patent: January 13, 2015Assignee: Medical Diagnostic Laboratories, LLCInventors: Martin E. Adelson, Melanie Feola, Jason Trama, Eli Mordechai
-
Publication number: 20140295463Abstract: The present invention is directed to a method of detecting a DEK protein in a human urine sample using an ELISA assay. Methods and compositions for detection of DEK using mAb 260-6F9F6 (as detection antibody) and mAb 16-2C9C3 (as capture antibody) in human urine are provided herein. Specifically, the ELISA assay utilizes a capture mAb and a detection mAb to yield a high sensitivity of <50 ng/mL. The presence of DEK in urine is useful in predicting or diagnosing the occurrence of bladder cancer in humans.Type: ApplicationFiled: April 22, 2014Publication date: October 2, 2014Applicant: MEDICAL DIAGNOSTIC LABORATORIES, LLCInventors: Antara Datta, Jason Trama
-
Patent number: 8741582Abstract: The present invention is directed to a method of detecting a DEK protein isoform 2 in a human urine sample using ELISA. Methods and compositions for detection of DEK isoform 2 in human urine are provided herein. The presence of DEK isoform 2 in urine is shown to correlate with bladder cancer in humans.Type: GrantFiled: October 20, 2011Date of Patent: June 3, 2014Assignee: Medical Diagnostic Laboratories, LLCInventors: Antara Datta, Jason Trama
-
Patent number: 8658376Abstract: The present invention is directed to a method of detecting DEK protein in a urine sample. Methods and compositions are provided herein for detecting and diagnosing bladder cancer by chemical-induced precipitation of urine proteins, followed by filtration-induced concentration and Western blot analysis to specifically detect DEK protein. The present method permits specific detection of DEK protein in urine as a biomarker for bladder cancer in humans.Type: GrantFiled: October 20, 2011Date of Patent: February 25, 2014Assignee: Medical Diagnostic Laboratories, LLCInventors: Antara Datta, Jason Trama
-
Publication number: 20130309683Abstract: Methods and compositions useful in the detection and identifcation of species of Candida are disclosed. The compositions are combinations of oligonucleotides, where the forward primers of the primer pairs have identical sequences, while each reverse primer of the primer pairs has a unique sequence relative to all of the other reverse primers; or the reverse primers of the primer pairs have identical sequences, while each forward primer of the primer pairs has a unique sequence relative to all of the other forward primers. The oligonucleotides also include probes capable of detecting these amplicons, and sequencing primers for determining, in primer extension reactions, the nucleotide sequences contained within the amplicons. The detection of an amplicon indicated that the sample contains at least one isolate of Candida ablicans, Candida glabrata, Candida parapsilosis, or Candida tropicalis, and the nucleotide sequence data is used to determine which of these four Candida species is present.Type: ApplicationFiled: July 5, 2013Publication date: November 21, 2013Applicant: MEDICAL DIAGNOSTIC LABORATORIES, LLCInventors: Jason Trama, Martin E. Adelson, Eli Mordechai
-
Publication number: 20130288238Abstract: Disclosed are methods and compositions for conducting assays utilizing real-time polymerase chain reactions (“PCRs”) in detection of serotypes L I, L II, and L III, but not stereotype B, of Chlamydia trachomatis, capable of causing lymphogranuloma venereum (“LGV”). These assays take advantage of a deletion occurring in the cytotoxin gene locus specific to the L I, L II, and L III serotypes. Each assay employs a first primer having a nucleotide sequence flanking one side of the deletion point and a second primer having a nucleotide sequence flanking the other side of the deletion point, wherein the first primer and the second primer are capable of hybridizing respectively to the plus strand and the minus strand of the genome of Chlamydia trachomatis during PCR. Synthesis during PCR of a sequence-specific amplicon containing this deletion point indicates that the sample contains nucleic acid specific to an LGV-causing serotype of Chlamydia trachomatis.Type: ApplicationFiled: October 23, 2012Publication date: October 31, 2013Inventors: Jason Trama, Eli Mordechai, Martin E. Adelson
-
Publication number: 20130230848Abstract: Methods for using oligonucleotides in the detection of Aspergillus fumigatus are disclosed. The oligonucleotides of the invention have nucleotide sequences derived from the gene encoding the cytochrome P450 14 alpha-sterol demethylase (the cyp51A protein) of Aspergillus fumigatus. The oligonucleotides include primers capable of producing amplicons specific to cyp51A in polymerase chain reactions using nucleic acids isolated from Aspergillus fumigatus as templates. The oligonucleotides also include probes capable of detecting these cyp51A-specific amplicons. The oligonucleotides of the invention also include primers for nucleotide sequencing reactions to determine whether an isolate of Aspergillus fumigatus is more tolerant than wild-type Aspergillus fumigatus to a triazole.Type: ApplicationFiled: September 17, 2012Publication date: September 5, 2013Applicant: MEDICAL DIAGNOSTIC LABORATORIES, LLCInventors: Jason Trama, Martin E. Adelson, Eli Mordechai
-
Publication number: 20130224738Abstract: The present invention provides a method of detecting DNA methylation of a plurality of genes consisting of CDKN2A, BCL2 and NID2 in a urine sample from a human. Methods and compositions are provided herein for detecting and diagnosing bladder cancer by obtaining a urine sample from a human subject suspected of bladder cancer, followed by detecting DNA methylation of CDKN2A, BCL2 AND NID2 in urine samples from the individual. The present method permits specific detection of DNA methylation of the selected gene promoters in urine as a biomarker for bladder cancer in humans.Type: ApplicationFiled: February 22, 2013Publication date: August 29, 2013Applicant: Medical Diagnostic Laboratories, LLCInventors: Michael Scher, Jason Trama